Navigation Links
DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
Date:8/18/2009

to be finished by late 2009 and the entire construction is slated for completion in 2010.

Orient Pharma is applying its platform technologies for the development of specialty pharmaceutical products and is capable of manufacturing pharmaceutical products under cGMP. Current technologies include multi-stage liquid fill and transdermal. Products under development include a next-generation drug to lower cholesterol, new combinations, as well as others indicated for cardiovascular, Alzheimer's disease, and neurodegenerative disorders. Orient Pharma will use its new facility to manufacture its own products and also to conduct contract manufacturing business for international pharmaceutical companies.

DURECT Forward-Looking Statement

The statements in this press release regarding ORADUR-ADHD, its potential attributes including tamper-resistant and once-a-day dosing characteristics, intended clinical trials and potential data generated therefrom, future development plans, potential commercialization of ORADUR-ADHD and royalties to be received by DURECT are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, difficulties or delays in the development, testing, regulatory approval, production and commercialization of ORADUR-ADHD, and unexpected adverse side-effects or inadequate therapeutic efficacy of ORADUR-ADHD that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials and tests are not necessarily indicative of future results of clinical trials and tests). Further information regarding these and other risks is included in DURECT's Form 10-Q dated August 4, 2009 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. DURECT Corporation Announces Second Quarter 2009 Financial
2. DURECT to Present at the BMO Capital Markets Healthcare Conference
3. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
4. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
5. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
6. DURECT to Participate in Cowen and Company Healthcare Conference
7. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
8. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
9. DURECT Corporation to Participate in Upcoming Healthcare Conferences
10. DURECT Corporation to Participate in Upcoming Healthcare Conferences
11. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...E, Fla., Nov. 30 The launch of Inv...lability of the first FDA-cleared, fully-automated...is by a radiologist of suspicious breast lesions. ...e Radiological Society of North America 2009 Annua...ip with leading experts in breast MRI, ONCAD for D...
(Date:11/30/2009)...mber 30, 2009 ― Providing free medications t...ients, lives at a relatively low cost for provinci...chers at St. Michael,s Hospital in Toronto. , "...escribed medications because they simply don,t fil... study,s lead author and a physician at St. Michae...
(Date:11/30/2009)...ls improve with specially designed program, study ...s) -- A special, intensive early intervention prog... IQ along with children,s language and social skil...hion, many children are able to learn and make rem...hor of the study, published online Nov. 30 in Pe...
(Date:11/30/2009)...S, N.J., Nov. 30 Kemin Foods, L.C..... and OmniActive Health Technologies, Ltd. ("OmniA...ir dispute. The parties agree that Kemin,s US Pate...ss for Isolation, Purification and Recrystallizati...d Uses Thereof" and the reissues of that patent ar...
(Date:11/30/2009)...R, Calif., Nov. 30 Ameri... ADHC) is pleased to announce the appointment of ...o the Company,s Board of Directors. Mr. McEldowney...iod starting at the Chemical Bank in New York City...etall & McEldowney, San Francisco, an institut...
Breaking Medicine News(10 mins):Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 2Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 3Health News:Coverage of inexpensive drugs may increase length and quality of life after heart attack 2Health News:Working Intensely Early on May Help Autistic Kids 2Health News:Working Intensely Early on May Help Autistic Kids 3Health News:Working Intensely Early on May Help Autistic Kids 4Health News:American Diversified Holdings Corporation Announces Appointment of Independent Director to the Board of the Company 2
...ISON, Texas, Nov. 12 ULURU Inc. (Amex:,ULU) today... to discuss the,third quarter 2007 financial resul...day, November 14, 2007 at 10:00 a.m. Eastern Time ...8 (access code 9283#) five to ten,minutes prior to...
... direction for Blaine Pharmaceuticals, CINCINNATI...that it has promoted Mark Rinker to Vice President...relations, market development activities,and sales...ceuticals, the company has gained,significant grou...
...It has long been assumed that consumers are good j...at how much youre willing to spend is influenced b...es (such as your bank account) or a smaller pool (...ng calories" Youre more likely to eat that slice o...
...EN BAY, Wis., Nov. 12 Shopko announced today the,...esident and Chief,Merchandising Officer. Jones wil...ising and marketing activities of the regional mas...ers. He,has over 20 years of retail leadership acr...
...ional Business Coalition on Health releases nation... According to the eValue8,(TM) report of health p...ational Business Coalition on Health (NBCH), healt...mer selection of,the best providers and member hea...
...Research out of the Neurological Institute at Univ...ep Brain Stimulation (DBS) helps patients who suff...kind study of five adults with TS determined that ...er characterized by sudden, repetitive muscle move...
Other Medicine News:Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update 2Health News:Mark Rinker Named Vice President of Sales for Blaine Pharmaceuticals 2Health News:Big ticket: You'll spend more thinking about your bank account than about your wallet 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 2Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 3
(Date:11/30/2009)..., , NEW YORK, Nov. 30 /PRNewswire/ ...search report is available in its catalogue: ,,..., http://www.reportlinker.com/p0164299/Surgical-I...cal incision closures market holds enormous signif... being performed each year. Surgical disciplines s...
(Date:11/30/2009)..., , NEW YORK, Nov. 30 /PRNewswire/ ...search report is available in its catalogue: ,,...or Balance the Immune Response ,, http://www....herapies-That-Suppress-or-Balance-the-Immune-Respo...y, either attacking an individual body or producin...
(Date:11/30/2009)..., , CHICAGO, Nov. 30 Dr. J...ing and Intervention at George Washington Universi...d how occult lesions identified with Breast-Specif... multi-modality imaging for needle biopsy as well,...nual meeting of the Radiological Society of North ...
Breaking Medicine Technology:Reportlinker Adds Surgical Incision Closures - Global Trends 2Reportlinker Adds Surgical Incision Closures - Global Trends 3Reportlinker Adds Surgical Incision Closures - Global Trends 4Reportlinker Adds Surgical Incision Closures - Global Trends 5Reportlinker Adds Surgical Incision Closures - Global Trends 6Reportlinker Adds Surgical Incision Closures - Global Trends 7Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico 14845 1NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico 14845 2NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico 14845 3Triage Wireless Inc Becomes Sotera Wireless Inc 6282 1nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open Chest Procedures 6278 1nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open Chest Procedures 6278 2
...ical Studies Presented at the Targeted,Anticancer ...ecular,Targets for Cancer Meetings Support Phase 1...20, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmac...s development-stage compound, SNS-314, at,two lead...ncer,medicines. Findings from in vitro and in vivo...
... published in an upcoming issue of,Anti-Cancer Dru...eutics Inc.,(TSX-V:PRX) today announced that two p...X 302. The Journal of the National Cancer,Institut... Sam,Denmeade and his team at Johns Hopkins Univer...paper describes the Company,s compound,PRX302, wh...
Other Medicine Technology:Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 2Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 3Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 2Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 3
...ourier* controls and monitors the movement of bloo... BloodTrack Courier provides a complete audit trai..., BloodTrack Courier electronically records a...ronment, from its receipt of blood products throug...
...ansconjunctival self-retaining infusion cannulas f...ay provide some benefit to patients that present w...ning the occurrence of suture induced astigmatism....nd does not require a blade for insertion. The reu...
...ent features a smooth, flat tip extending from the...designed tip is used to efficiently chop and manip...r capsule. The end opening port supplies maximum ...ge should the end port become occluded, especially...
... developed and patented a new, smaller and faster ...uted tomography (SPECT) with twice the resolution ...ll as an executive chair, runs on 110 Volts AC and...modeling. The device has no visible moving parts a...
Medicine Products: